The Korea Herald has reported that Celltrion Inc., a South Korean biopharmaceutical firm, is seeking approval from the European Medicines Agency (EMA) for the sale of CT-P16, Celltrion’s anticancer biosimilar candidate.  CT-P16 references Avastin (Bevacizumab), which is indicated for the treatment of various types of cancers, including colorectal, lung, and kidney cancer.  As we previously shared, CT-P16 is among several investigational biosimilars in Celltrion’s pipeline, including CT-P17 (referencing Humira), CT-P39 (referencing Xolaire), CT-P41 (referencing Prolia), CT-P42 (referencing Eylea), and CT-P43 (referencing Stelara).